CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 63 filers reported holding CUE BIOPHARMA INC in Q1 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,736,564 | -37.0% | 755,028 | 0.0% | 0.43% | -23.4% |
Q2 2023 | $2,755,852 | +2.2% | 755,028 | 0.0% | 0.56% | -2.8% |
Q1 2023 | $2,695,450 | +9.8% | 755,028 | -12.3% | 0.58% | +7.9% |
Q4 2022 | $2,454,642 | +98.3% | 861,278 | +55.2% | 0.53% | +106.6% |
Q3 2022 | $1,238,000 | -10.4% | 555,000 | 0.0% | 0.26% | -9.5% |
Q2 2022 | $1,382,000 | -48.7% | 555,000 | +0.5% | 0.28% | -40.4% |
Q1 2022 | $2,694,000 | +19.1% | 552,000 | +176.0% | 0.48% | +35.4% |
Q4 2021 | $2,262,000 | -11.3% | 200,000 | +14.3% | 0.35% | -14.7% |
Q3 2021 | $2,550,000 | +25.1% | 175,000 | 0.0% | 0.41% | +34.4% |
Q2 2021 | $2,039,000 | +11.4% | 175,000 | +16.7% | 0.31% | +97.4% |
Q1 2021 | $1,830,000 | +95.1% | 150,000 | +100.0% | 0.16% | -14.8% |
Q4 2020 | $938,000 | -58.5% | 75,000 | -50.0% | 0.18% | -54.7% |
Q3 2020 | $2,258,000 | -44.2% | 150,000 | -9.1% | 0.40% | -43.5% |
Q2 2020 | $4,044,000 | +72.7% | 165,000 | 0.0% | 0.72% | +16.8% |
Q1 2020 | $2,341,000 | -10.6% | 165,000 | 0.0% | 0.61% | +47.5% |
Q4 2019 | $2,619,000 | – | 165,000 | – | 0.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Corriente Advisors, LLC | 1,915,219 | $23,959,000 | 5.70% |
Prosight Management, LP | 906,569 | $11,341,000 | 5.24% |
P.A.W. CAPITAL CORP | 140,000 | $1,751,000 | 1.54% |
Voss Capital, LLC | 220,714 | $2,761,000 | 1.39% |
Robertson Stephens Wealth Management, LLC | 484,000 | $6,054,000 | 1.26% |
Slate Path Capital LP | 1,483,619 | $18,560,000 | 1.00% |
Nantahala Capital Management | 2,506,772 | $31,360,000 | 0.97% |
PRECEPT MANAGEMENT LLC | 150,000 | $1,877,000 | 0.76% |
SANDERS MORRIS HARRIS LLC | 193,591 | $2,449,000 | 0.56% |
Rock Creek Group, LP | 100,014 | $1,251,000 | 0.51% |